African Institute of Public Health, 12 P.O. Box. 199 Ouagadougou, Burkina Faso.
Research Institute for Health Sciences, P.O. Box 7192 Ouagadougou, Burkina Faso.
Biomed Res Int. 2023 Feb 7;2023:8735563. doi: 10.1155/2023/8735563. eCollection 2023.
This systematic review was conducted to provide up-to-date evidence on the safety and effectiveness of task sharing in the delivery of modern contraceptives. . The review followed the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines. We searched Medline, Embase, Cochrane CENTRAL, and Google Scholar for peer-reviewed studies that reported on effectiveness and/or safety outcomes of task sharing of any modern contraceptive method. Only Cochrane Effective Practice of Organizations of Care (EPOC) study designs were eligible, and quality assessment of the evidence was performed using the Cochrane risk of bias (RoB) tools. Meta-analyses, where possible, were carried out using Stata, and certainty of the evidence for outcomes was assessed using the Grading of Recommendations Assessment, Development, and Evaluation tool (GRADE).
Six studies met the inclusion criteria: five reported on self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) compared to administered by trained health providers; and one assessed tubal ligation performed by associate clinicians compared to advanced-level associate clinicians. Self-injection improved contraceptive continuation, with no increase in unintended pregnancy and no difference in side effects compared to provider administered. In tubal ligation, the rate of adverse events, time to complete procedure, and participant satisfaction were similar among associate clinicians and advanced clinicians.
The evidence suggests that self-injection of DMPA-SC and tubal ligation performed by associate clinicians are safe and effective. These findings should be complemented with the evidence on the feasibility and acceptability of task sharing of these methods. The review protocol was registered with PROSPERO CRD42021283336.
本系统评价旨在提供最新证据,说明在提供现代避孕药具方面任务分担的安全性和有效性。本评价遵循系统评价和荟萃分析的首选报告项目(PRISMA)指南。我们在 Medline、Embase、Cochrane 中心数据库和 Google Scholar 中搜索了报道任何现代避孕药具方法任务分担的有效性和/或安全性结果的同行评议研究。只有符合 Cochrane 组织护理实践有效性(EPOC)研究设计的研究才符合入选标准,并且使用 Cochrane 偏倚风险(RoB)工具对证据质量进行了评估。在可能的情况下,使用 Stata 进行了荟萃分析,并使用推荐评估、制定与评估工具(GRADE)评估结果的证据确定性。
六项研究符合纳入标准:五项研究报告了皮下注射 depot 醋酸甲羟孕酮(DMPA-SC)的自我注射与由经过培训的卫生提供者给药相比;一项研究评估了由助理临床医生进行的输卵管结扎术与高级助理临床医生进行的输卵管结扎术相比。自我注射提高了避孕的持续率,与由提供者给药相比,意外怀孕率没有增加,副作用也没有差异。在输卵管结扎术方面,助理临床医生和高级临床医生的不良事件发生率、完成手术的时间和患者满意度相似。
证据表明,DMPA-SC 的自我注射和由助理临床医生进行的输卵管结扎术是安全有效的。这些发现应该与这些方法的任务分担的可行性和可接受性的证据相结合。本评价方案已在 PROSPERO CRD42021283336 上注册。